EGFR and cervical cancer: By analyzing the EGFR activity scores in transcriptomic data on patients with TCGA cervical cancer patients classified as responders (R, complete or partial response) or non-responders (NR, stable or progressive disease) to cisplatin alone treatment, we found that EGFR activity scores were statistically higher in NR than in R (Fig. 1b).